Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Classifica tra le azioni
#3628
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Prezzo delle azioni
$3.71
Capitalizzazione di mercato
$4.69B
Variazione (1 giorno)
2.44%
Variazione (1 anno)
-51.92%
Paese
CN
Scambia Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Categoria
Healthcare
Rapporto P/S per Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Rapporto P/S al October 2026 TTM: 15.67
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., il rapporto P/S attuale (TTM) è 15.67. Alla fine del 2023, era pari a 17.18.
Storico del rapporto P/S per Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. da 2013 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 15.67 | -62.38% |
| 2024 | 41.67 | 142.53% |
| 2023 | 17.18 | 69.95% |
| 2022 | 10.11 | -48.04% |
| 2021 | 19.46 | -35.13% |
| 2020 | 29.99 | 775.33% |
| 2019 | 3.43 | -14.52% |
| 2018 | 4.01 | 1.37% |
| 2017 | 3.95 | -11.91% |
| 2016 | 4.49 | -19.44% |
| 2015 | 5.57 | -11.75% |
| 2014 | 6.31 | -13.45% |
| 2013 | 7.30 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | -36.06% |
US
|
|
| 40.55 | 158.70% |
US
|
|
| 3.96 | -74.73% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -35.27% |
NL
|
